附近上门

After receiving U.S. Food and Drug Administration clearance for treatment pertaining to its RefleXion X1 machine, therapeutic oncology company RefleXion Medical has closed on a $100 million equity financing.

Subscribe to the 附近上门 Daily

, one of Canada鈥檚 largest pension investment managers, led the financing for Hayward, California-based .

Existing investors, , KCK Group, , , , and , all participated in the round.

鈥淩efleXion鈥檚 bold vision for the future of cancer care stands to completely reshape how physicians think about treating patients with stage 4 cancer,鈥� Lo茂c Jul茅, managing director for PSP Investments鈥� Global Investment Partnerships Portfolio, said in a written statement. 鈥淲e are thrilled to support RefleXion during this next phase of their growth as they ramp up market and clinical adoption of this groundbreaking technology.鈥�

PSP most recently of funding for SitusAMC, a Denver-based provider of consulting, outsourcing, talent and technology solutions.

Meanwhile, RefleXion of funding in April 2018, making total funding raised at $223.6 million, according to 附近上门 data.

Founded in 2009, the company is working on the use of biology-guided radiotherapy for all stages of cancer. Simply put, the RefleXion X1 machine uses imaging on a tumor to deliver a precise therapeutic dose of radiation for that tumor. for that therapy in March.

in May 2019 to build the machine, and Todd Powell, president and CEO, said in a written statement that the company expects to begin shipping the machines in the third quarter of 2020.

鈥淭he support of this top-tier investment syndicate enables us to further scale operations around commercializing the X1 platform,鈥� he said. 鈥淢oreover, these funds allow us to validate the practical implications of using BgRT on a daily basis as we transform radiotherapy from early-stage cancer treatment to an option for patients with all stages of cancer.鈥�

Illustration: